Business Wire

Lifespin GmbH Secures €2.5M Bridge Financing to Further Build its AI-Enabled Metabolomics-Based Differential Diagnosis Panel for Neurological Diseases

Share

Lifespin GmbH, a deep data company currently developing a proprietary AI-based health testing platform to measure quantitative metabolic data in patient samples, has secured €2.5M bridge financing to fuel the company’s continued product development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005059/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The metabolic status of an individual is measured quantitatively with NMR and processed with lifespin™ proprietary advanced artificial intelligence (AI) and deep learning algorithms for the determination of health status and diagnosis of diseases and results are delivered via the cloud. (Image: Lifespin GmbH)

The Lifespin platform is based on mapping metabolomics for human health and translating that data into health information that can be deployed in a wide range of pharmaceutical, research, and clinical settings. Lifespin’s health diagnostics software will be applicable in the broader healthcare space ranging from diagnostics to patient stratification and personalized medicine, as well as supporting the drug discovery process.

“We are very excited about Lifespin’s growth trajectory with a platform solution which can be accessed by collaborating clinical laboratories and drug discovery partners and scale globally via our cloud solutions,” said Lifespin’s CEO, Dr. Ali Tinazli.

The bridge financing will be used to continue the development of the first diagnostics panel for neurological diseases such as multiple sclerosis and Parkinson’s disease, some of which cannot be addressed with legacy laboratory-based methods. The first commercial test of the differential diagnostics panel will be covering early stages of multiple sclerosis. The panel will be further expanded with other neurological indications over time.

“Lifespin’s new software-based approach to digitally capture, compare and analyze human metabolomes will open up a new and exciting field, complementary to existing health diagnostics,” said Robert Wieland, Managing Director of Wieland Capital and Lifespin’s lead investor.

Lifespin expects to begin fundraising for a Series A in 2022 to fund its first product introductions and to support expanding its business operations to the United States.

# # #

Lifespin (www.lifespin.ai) is a deep data company that maps human health based on metabolomics. Lifespin’s advisory board consists of key opinion leaders such as James Rothman (Nobel Laureate in Physiology/Medicine, Sterling Professor of Cell Biology, Yale University, New Haven, CT USA) and numerous industry veterans. We have standardized the baseline for human health and can detect distinct deviations caused by diseases. A pathogenesis impacts metabolism, causing specific changes in the presence and quantity of metabolites. Our proprietary technology platform quantitatively captures individual metabolomes, i.e., up to hundreds of metabolite concentrations with a single Nuclear Magnet Resonance (NMR) measurement. Lifespin is building a proprietary in-house biobank with currently 200,000 human blood samples and performing quantitative in-house measurements of metabolomes for systematic mapping across health conditions. Our constantly growing proprietary database of digitized metabolic profiles enables the analysis of billions of metabolic relationships. Digital metabolic profiles enable differential diagnosis for the early detection of health conditions, staging of diseases, monitoring of treatment success and personalized medicine. Our first regulatory approved Software-as-IVD will be for the early differential diagnosis of multiple sclerosis and is expected in 2022. This will be followed by other tests for the detection of neurological, cancer, and inflammatory diseases. Our cloud-based business model is built on our proprietary Software-as-a-Service (SaaS) platform for diagnostics and health information and is globally scalable.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dr. Ali Tinazli, CEO, Lifespin GmbH
ali.tinazli@lifespin.ai +49 941-942-898-12 and +1 310-467-1112

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee21.1.2022 17:00:00 CET | Press release

Altasciences is pleased to have been chosen by Virpax® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ:VRPX) to conduct a first-in-human study of Epoladerm™ (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film. The study will be conducted in Q2 2022 at Altasciences’ clinical pharmacology unit in Montreal, Canada. “We look forward to working with Altasciences to accelerate the development of this analgesic treatment and provide robust data in support of the 505(b)(2) FDA approval pathway,” stated Virpax’s Chairman & CEO, Anthony P. Mack. Virpax’s proprietary technology provides a pre-filled canister for the therapeutic application of a clear, fast-drying spray film that is thinner than a standard liquid bandage. This technology offers convenience and eliminates the need for messy creams or gels. Altasciences leverages decades of experience conducting first-in-human clinic

OMRON Healthcare Remote Patient Monitoring Services Win “Best of” Honors at CES 202221.1.2022 16:21:00 CET | Press release

OMRON Healthcare, Inc., the global leader in remote blood pressure monitoring and personal health technology, spotlighted its new remote patient monitoring services at the 2022 Consumer Electronics Show (CES) and won “Best of” honors for its offerings in the U.K. and U.S: Hypertension Plus by OMRON in the U.K. was selected as a TWICE Picks Awards winner for the 2022 TWICE, Residential Systems and TechRadar Pro Picks Awards VitalSight™ by OMRON in the U.S. was recognised as an INSIDER “Best of” CES selection These remote patient monitoring services gained recognition at the world’s largest innovation show as breakthrough health technology designed to foster greater active health condition management, strengthen the patient-physician connection, and guide behavior change to reduce health risks, while advancing the company’s mission of Going for Zero heart attacks and strokes. “OMRON developed Hypertension Plus as the first step toward transforming chronic care in the U.K., while VitalSig

Schlumberger Announces Fourth-Quarter and Full-Year 2021 Results21.1.2022 12:50:00 CET | Press release

Schlumberger Limited (NYSE: SLB) today reported results for the fourth-quarter and full-year 2021. Fourth-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeDec. 31, 2021Sept. 30, 2021Dec. 31, 2020SequentialYear-on-yearRevenue* $6,225 $5,847 $5,532 6% 13% Income before taxes - GAAP basis $755 $691 $471 9% 60% Net income - GAAP basis $601 $550 $374 9% 61% Diluted EPS - GAAP basis $0.42 $0.39 $0.27 8% 56% Adjusted EBITDA** $1,381 $1,296 $1,112 7% 24% Adjusted EBITDA margin** 22.2% 22.2% 20.1% 2 bps 208 bps Pretax segment operating income** $986 $908 $654 9% 51% Pretax segment operating margin** 15.8% 15.5% 11.8% 31 bps 401 bps Net income, excluding charges & credits** $587 $514 $309 14% 90% Diluted EPS, excluding charges & credits** $0.41 $0.36 $0.22 14% 86% Revenue by Geography International $4,898 $4,675 $4,343 5% 13% North America* 1,281 1,129 1,167 13% 10% Other 46 43 22 n/m n/m $6,225 $5,847 $5,532 6% 13% *Schlumberger divested certain businesses i

ZuluTrade - World’s Largest Social Trading Platform Joins the Finvasia Group21.1.2022 12:08:00 CET | Press release

ZuluTrade is strongly positioned to become the biggest and the largest broker neutral social trading platform with acquisition by Finvasia Group. 2022 will see ZuluTrade strengthening its current capabilities and widen its product line by venturing into different markets and financial instruments. The expansion will include contemporary asset classes like cryptocurrencies and traditional asset classes like stocks and bonds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220120005780/en/ ZuluTrade - World’s Largest Social Trading Platform Joins the Finvasia Group (Graphic: Business Wire) ZuluTrade has been at the forefront of copy trading for more than a decade and has helped over a million investors across more than 100 countries trade a volume of over USD 2 trillion. ZuluTrade 2.0 Future plans include launching a more engaging social investing platform with enhanced social and technology features, built on ZuluTrade’s curre

Ipsen Nominates Karen Witts as New Independent Board Member21.1.2022 07:00:00 CET | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220120006035/en/ Karen Witts (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) announced today the nomination of Karen Witts to its Board of Directors as independent member. Karen Witts was Group CFO at Compass Group Plc until October 2021. Compass is the world’s leading food service company, operating in 43 countries and employing more than 500k people. She was responsible for corporate strategy and planning, business performance management and reporting, financial reporting and control, tax and treasury activities, M&A, internal audit and enterprise risk management, investor relations, and led the digital and technology function. Prior to this, Karen was Group CFO at Kingfisher Plc, the international home improvement company. She has also held various senior strategic finance positions at companies including Vodafone Group Services Ltd, and BT Plc. She

Peru Is Presenting Itself at FITUR 2022 as a Bio-safe Destination, Committed to Outdoor Experiences21.1.2022 02:48:00 CET | Press release

Peru is in attendance at the 42nd edition of FITUR 2022 to position itself as a safe and ready destination for international travellers, motivating them to rediscover the South American country, reported the Comisión de Promoción del Perú para la Exportación y el Turismo [Peruvian Export and Tourism Promotion Commission] (PROMPERÚ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005812/en/ Inauguration of the Peru stand at FITUR 2022 by the executive president of PROMPERÚ, Amora Carbajal. ©PROMPERÚ In line with its promotion and recovery strategy, Peru is presenting a delegation made up of 19 co-exhibitors in order to show off the best of its tourist offering in the nature, adventure and culture segments. Likewise, it announced its collaboration with the Asociación Española de Agencias de Incentivos – IdeMICE, in order to enhance the attributes of the destination in this segment. In addition, the executive president of

McAfee Continues to Provide Leading Online Protection to Consumers21.1.2022 02:40:00 CET | Press release

Today, McAfee Corp. (NASDAQ: MCFE, “McAfee”), a global leader in online protection, provided an update regarding its pure-play consumer offering and the previously announced divestiture of its enterprise business. In July 2021, McAfee completed the sale of its enterprise business. This transaction allowed McAfee to singularly focus on its consumer business and accelerate its strategy to be the leader in online protection for consumers. “McAfee continues to safeguard the privacy, security and identity of our consumers as the digital world evolves rapidly,” said Gagan Singh, Executive Vice President & Chief Revenue and Product Officer, McAfee. “We continue to stand firm that meaningful protection is a personal right for consumers and have recently rolled out major updates and industry firsts, including McAfee Total Protection and Protection Score, that look out for consumers online, including their privacy and identity.” The McAfee Enterprise business was purchased by Symphony Technology

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom